Published July 13, 2011
Northwestern Innovations and New Ventures Office
Assistant Professor C. Shad Thaxton describes how his company, Aurasense, has made the leap from a university research lab to the marketplace.
AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform
C&EN News Explores Immune Modulating Capabilities of SNA Technology
Biotuesdays: In Conversation with David Giljohann
AuraSense Therapeutics Adds to Series C Financing
David Giljohann Named Among Top 40 Under 40 by Analytical Scientist